It produces more modest results than semaglutide or tirzepatide, typically around 8 percent body weight loss, but it was the first GLP-1 to receive FDA approval specifically for weight management and remains a viable option for patients who prefer a shorter-acting medication or who experience intolerable side effects on the more potent formulations
As manufacturers continue to develop more accessible, durable, and patientfriendly delivery systems, the adoption of GLP1 receptor agonists is expected to rise further, reinforcing their market leadership and supporting sustained growth in the market
Inject a small amount of air first to break the vacuum, then add your bacteriostatic water at a controlled speed
Shanmugam G, Challa AK, Litovsky SH, Devarajan A, Wang D, Jones DP, et al